In a new study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs ...

Researchers at the University of Copenhagen have developed a new weight-loss drug that may surpass the effectiveness of ...

Type 2 diabetes has become increasingly pervasive, driven by the complex interplay between genetic predisposition and modern ...

The FDA has given the green light to a clinical trial testing ATA-200, a gene therapy for limb-girdle muscular dystrophy ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

The criminal justice forensic sector has been strengthened thanks to an acquisition deal brokered by Northampton’s corporate ...

Me just dropped some major news in a tough year for the genetic testing company. After months of financial challenges, data ...

The company announced Monday that it would lay off around 40% of its workforce -- about 200 employees -- and close its drug ...

Lin said he went through two or three iterations of testing nearly 100 potential solutions before he found one that could be ...

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile ...